Ratings by Oppenheimer (Hartaj Singh)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/26/2024 | Astria Therapeutics | ATXS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/14/2024 | Spruce Biosciences, Inc. | SPRB | Maintain | Outperform (N/A) |
|
Details | ||
| 2/12/2024 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 1/31/2024 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 1/26/2024 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 1/25/2024 | Inovio Pharmaceuticals | INO | Upgrade | Outperform (Perform) |
0.58 (10.47) |
1705.17% | Details | |
| 1/9/2024 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 1/5/2024 | Entrada Therapeutics | TRDA | New Coverage | Outperform (N/A) |
13.80 (13.33) |
-3.41% | Details | |
| 1/5/2024 | Harpoon Therapeutics | HARP | New Coverage | Outperform (N/A) |
10.53 (23.01) |
118.52% | Details | |
| 1/5/2024 | BioNTech | BNTX | New Coverage | Perform (N/A) |
110.07 (88.71) |
-19.41% | Details | |
| 1/2/2024 | Moderna | MRNA | Upgrade | Outperform (Perform) |
99.45 (107.61) |
8.21% | Details | |
| 12/26/2023 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 12/22/2023 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 12/12/2023 | Biomea Fusion Inc. | BMEA | Maintain | Outperform (N/A) |
|
Details | ||
| 11/15/2023 | Astria Therapeutics | ATXS | Maintain | Outperform (N/A) |
|
Details | ||
| 11/2/2023 | Eloxx Pharma | ELOX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/31/2023 | Sarepta Therapeutics | SRPT | Downgrade | Perform (Outperform) |
107.65 (119.39) |
10.91% | Details | |
| 9/14/2023 | Eloxx Pharma | ELOX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/13/2023 | Opthea Ltd. | OPT | Maintain | Outperform (N/A) |
|
Details | ||
| 8/21/2023 | Regeneron Pharma | REGN | Maintain | (N/A) |
|
Details | ||
| 8/21/2023 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/18/2023 | Spruce Biosciences, Inc. | SPRB | Maintain | Outperform (N/A) |
|
Details | ||
| 8/4/2023 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 7/11/2023 | Eloxx Pharma | ELOX | Maintain | Outperform (N/A) |
|
Details | ||
| 7/5/2023 | aTyr Pharma | LIFE | Downgrade | Perform (Outperform) |
2.23 (1.63) |
-26.91% | Details | |
| 6/26/2023 | Allogene | ALLO | New Coverage | Outperform (N/A) |
4.70 (3.50) |
-25.53% | Details | |
| 6/13/2023 | Orchard Therapeutics | ORTX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/24/2023 | Icosavax Inc. | ICVX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/12/2023 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 5/10/2023 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/2/2023 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 4/25/2023 | Icosavax Inc. | ICVX | Maintain | Outperform (N/A) |
|
Details | ||
| 4/4/2023 | Oncternal Therapeutics | ONCT | Downgrade | Perform (Outperform) |
0.79 (9.00) |
1039.24% | Details | |
| 3/29/2023 | Biomea Fusion Inc. | BMEA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/27/2023 | Viracta Therapeutics | VIRX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/22/2023 | Oncternal Therapeutics | ONCT | Maintain | Outperform (N/A) |
|
Details | ||
| 3/13/2023 | Orchard Therapeutics | ORTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/13/2023 | Opthea Ltd. | OPT | Maintain | Outperform (N/A) |
|
Details | ||
| 3/13/2023 | Cellectis | CLLS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/9/2023 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 3/1/2023 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 1/4/2023 | Icosavax Inc. | ICVX | New Coverage | Outperform (N/A) |
7.94 (15.31) |
92.82% | Details | |
| 12/20/2022 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 11/25/2022 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 11/25/2022 | Gain Therapeutics | GANX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/17/2022 | Spruce Biosciences, Inc. | SPRB | Maintain | Outperform (N/A) |
|
Details | ||
| 11/11/2022 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/8/2022 | Cellectis | CLLS | Maintain | Outperform (N/A) |
|
Details | ||
| 11/3/2022 | United Therapeutics Corp. | UTHR | Maintain | Outperform (N/A) |
|
Details | ||
| 10/21/2022 | NeuBase Therapeutics | NBSE | Downgrade | Perform (Outperform) |
0.29 (0.43) |
48.28% | Details | |
| 8/22/2022 | NeuBase Therapeutics | NBSE | Maintain | Outperform (N/A) |
|
Details | ||
| 8/18/2022 | Biomea Fusion Inc. | BMEA | Maintain | Outperform (N/A) |
|
Details | ||
| 8/16/2022 | aTyr Pharma | LIFE | Maintain | Outperform (N/A) |
|
Details | ||
| 8/4/2022 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 7/18/2022 | Orchard Therapeutics | ORTX | New Coverage | Outperform (N/A) |
0.60 (16.70) |
2683.33% | Details | |
| 5/11/2022 | Inovio Pharmaceuticals | INO | Downgrade | Perform (Outperform) |
2.49 (0.58) |
-76.71% | Details | |
| 4/4/2022 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/18/2022 | aTyr Pharma | LIFE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/2/2022 | Inovio Pharmaceuticals | INO | Maintain | Outperform (N/A) |
|
Details | ||
| 2/8/2022 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/3/2022 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 1/12/2022 | United Therapeutics Corp. | UTHR | Maintain | Outperform (N/A) |
|
Details | ||
| 1/4/2022 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 12/17/2021 | Biomea Fusion Inc. | BMEA | New Coverage | Outperform (N/A) |
8.29 (11.11) |
34.02% | Details | |
| 12/17/2021 | Spruce Biosciences, Inc. | SPRB | New Coverage | Outperform (N/A) |
2.50 (0.72) |
-71.2% | Details | |
| 12/17/2021 | Eloxx Pharma | ELOX | New Coverage | Outperform (N/A) |
0.69 (3.82) |
453.62% | Details | |
| 12/9/2021 | Sarepta Therapeutics | SRPT | Upgrade | Outperform (Perform) |
85.95 (119.39) |
38.91% | Details | |
| 11/10/2021 | Inovio Pharmaceuticals | INO | Maintain | Outperform (N/A) |
|
Details | ||
| 9/24/2021 | Astria Therapeutics | ATXS | Maintain | Outperform (N/A) |
|
Details | ||
| 9/21/2021 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 9/14/2021 | aTyr Pharma | LIFE | Maintain | Outperform (N/A) |
|
Details | ||
| 9/9/2021 | United Therapeutics Corp. | UTHR | Maintain | Outperform (N/A) |
|
Details | ||
| 9/8/2021 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 8/6/2021 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/6/2021 | Moderna | MRNA | Downgrade | Perform (Outperform) |
416.26 (107.61) |
-74.15% | Details | |
| 7/15/2021 | Opthea Ltd. | OPT | Maintain | Outperform (N/A) |
|
Details | ||
| 7/2/2021 | Inovio Pharmaceuticals | INO | Maintain | Outperform (N/A) |
|
Details | ||
| 6/22/2021 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 5/5/2021 | Alexion Pharmaceuticals | ALXN | New Coverage | Outperform (N/A) |
170.27 (182.01) |
6.89% | Details | |
| 4/16/2021 | Inovio Pharmaceuticals | INO | Maintain | Outperform (N/A) |
|
Details | ||
| 4/16/2021 | Oncternal Therapeutics | ONCT | Maintain | Outperform (N/A) |
|
Details | ||
| 4/12/2021 | Gain Therapeutics | GANX | New Coverage | Outperform (N/A) |
13.98 (3.17) |
-77.32% | Details | |
| 4/7/2021 | Oncternal Therapeutics | ONCT | New Coverage | Outperform (N/A) |
8.25 (9.00) |
9.09% | Details | |
| 3/24/2021 | aTyr Pharma | LIFE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/11/2021 | Catabasis | CATB | Upgrade | Outperform (Perform) |
2.92 (8.54) |
192.47% | Details | |
| 3/3/2021 | Sarepta Therapeutics | SRPT | Maintain | Perform (N/A) |
|
Details | ||
| 2/26/2021 | Viracta Therapeutics | VIRX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/23/2021 | Sunesis Pharmaceuticals Inc. | SNSS | Upgrade | Outperform (Perform) |
3.66 (5.32) |
45.36% | Details | |
| 2/16/2021 | United Therapeutics Corp. | UTHR | Maintain | Outperform (N/A) |
|
Details | ||
| 2/12/2021 | Inovio Pharmaceuticals | INO | New Coverage | Outperform (N/A) |
12.98 (10.47) |
-19.34% | Details | |
| 2/1/2021 | Moderna | MRNA | Maintain | Outperform (N/A) |
|
Details | ||
| 1/20/2021 | United Therapeutics Corp. | UTHR | Maintain | Outperform (N/A) |
|
Details | ||
| 12/31/2020 | United Therapeutics Corp. | UTHR | Maintain | Outperform (N/A) |
|
Details | ||
| 12/30/2020 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/21/2020 | Moderna | MRNA | Maintain | Outperform (N/A) |
|
Details | ||
| 12/17/2020 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 11/16/2020 | Moderna | MRNA | Maintain | Outperform (N/A) |
|
Details | ||
| 11/12/2020 | Strongbridge Biopharma | SBBP | Maintain | Outperform (N/A) |
|
Details | ||
| 11/11/2020 | Opthea Ltd. | OPT | New Coverage | Outperform (N/A) |
13.19 (3.43) |
-74% | Details | |
| 10/29/2020 | United Therapeutics Corp. | UTHR | Maintain | Outperform (N/A) |
|
Details | ||
| 10/27/2020 | Catabasis | CATB | Downgrade | Perform (Outperform) |
5.36 (8.54) |
59.33% | Details | |
| 9/10/2020 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 9/8/2020 | Strongbridge Biopharma | SBBP | Maintain | Outperform (N/A) |
|
Details | ||
| 8/14/2020 | aTyr Pharma | LIFE | Maintain | Outperform (N/A) |
|
Details | ||
| 8/6/2020 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 7/30/2020 | United Therapeutics Corp. | UTHR | Maintain | Outperform (N/A) |
|
Details | ||
| 7/1/2020 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 6/23/2020 | Sunesis Pharmaceuticals Inc. | SNSS | Downgrade | Perform (Outperform) |
0.62 (3.66) |
490.32% | Details | |
| 5/18/2020 | Moderna | MRNA | Maintain | Outperform (N/A) |
|
Details | ||
| 5/1/2020 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 4/20/2020 | United Therapeutics Corp. | UTHR | Maintain | Outperform (N/A) |
|
Details | ||
| 4/15/2020 | Moderna | MRNA | Maintain | Outperform (N/A) |
|
Details | ||
| 4/15/2020 | Moderna | MRNA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/17/2020 | Alexion Pharmaceuticals | ALXN | Downgrade | Perform (Outperform) |
75.56 (182.01) |
140.88% | Details | |
| 3/11/2020 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/11/2020 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/2/2020 | aTyr Pharma | LIFE | New Coverage | Outperform (N/A) |
3.71 (1.63) |
-56.06% | Details | |
| 1/22/2020 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 1/8/2020 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/30/2019 | Sarepta Therapeutics | SRPT | Maintain | Perform (N/A) |
|
Details | ||
| 11/8/2019 | Strongbridge Biopharma | SBBP | Maintain | Outperform (N/A) |
|
Details | ||
| 11/8/2019 | Catabasis | CATB | Maintain | Outperform (N/A) |
|
Details | ||
| 11/6/2019 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 10/25/2019 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 10/24/2019 | Alexion Pharmaceuticals | ALXN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/15/2019 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 7/12/2019 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 7/11/2019 | ArQule | ARQL | Maintain | Outperform (N/A) |
|
Details | ||
| 6/14/2019 | ArQule | ARQL | Maintain | Outperform (N/A) |
|
Details | ||
| 6/5/2019 | ArQule | ARQL | Maintain | Outperform (N/A) |
|
Details | ||
| 5/29/2019 | Moderna | MRNA | Maintain | Outperform (N/A) |
|
Details | ||
| 4/24/2019 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/23/2019 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 4/9/2019 | United Therapeutics Corp. | UTHR | Maintain | Outperform (N/A) |
|
Details | ||
| 4/8/2019 | Sarepta Therapeutics | SRPT | Maintain | Perform (N/A) |
|
Details | ||
| 3/19/2019 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 3/15/2019 | Catabasis | CATB | Maintain | Outperform (N/A) |
|
Details | ||
| 3/8/2019 | Sunesis Pharmaceuticals Inc. | SNSS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/8/2019 | ArQule | ARQL | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/7/2019 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/25/2019 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/12/2019 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 2/7/2019 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 1/29/2019 | Sarepta Therapeutics | SRPT | Maintain | Perform (Perform) |
|
Details | ||
| 1/14/2019 | Catabasis | CATB | Maintain | Outperform (N/A) |
|
Details | ||
| 1/3/2019 | Gilead Sciences | GILD | Upgrade | Outperform (Perform) |
62.55 (67.40) |
7.75% | Details | |
| 11/8/2018 | Pieris Pharmaceuticals | PIRS | Maintain | Outperform (N/A) |
|
Details | ||
| 10/29/2018 | Syndax Pharmaceuticals | SNDX | Maintain | Perform (N/A) |
|
Details | ||
| 8/14/2018 | Strongbridge Biopharma | SBBP | Maintain | Outperform (N/A) |
|
Details |
